Zinc-dependent thymic peptide hormone · Fact sheet
Thymulin
Also known as Facteur thymique serique · FTS
Thymulin is a thymus-derived peptide whose biological activity depends on zinc. Immune-cell and animal findings do not establish that administering it improves human immunity or treats autoimmune disease.
What is Thymulin?
The active hormone is a zinc-associated nonapeptide. Measuring endogenous thymulin is different from testing a supplied peptide.
Thymulin gene-delivery experiments also differ from administering the isolated hormone.
Benefits & claims
Interest centers on T-cell development, inflammatory signaling and thymus-related aging.
What the evidence supports
- Thymulin altered selected cytokines in cultured immune cells from healthy volunteers and lupus patients, with context-dependent effects.
- A mouse gene-delivery experiment improved experimental asthma pathology; it did not test a human thymulin injection.
- Changes in endogenous thymulin after zinc supplementation are not evidence that an administered peptide is effective.
Research areas
- Thymic hormone biology
- Immune-cell signaling
- Experimental allergic asthma
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for Thymulin. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- The active hormone is a zinc-associated nonapeptide. Measuring endogenous thymulin is different from testing a supplied peptide.
Formulation differences
- Thymulin gene-delivery experiments also differ from administering the isolated hormone.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Human therapeutic benefit
- Formulation, zinc association and stability
- Autoimmune-disease effects and long-term safety
Side effects & risks
- Human administered-peptide safety and immune effects are insufficiently characterized.
- A substance with immune activity may behave differently across disease states; the cited cell results are not a universal immune boost.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Mostly animal or lab researchThe cited human material is an in-vitro immune-cell study and an endogenous-hormone study during zinc supplementation. The asthma treatment experiment used gene-delivery nanoparticles in mice.
Studies
In-vitro experiment, not administered human treatment.
Nanoparticle gene-delivery study in an animal model.
Crohn disease study of zinc, not a thymulin regimen.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
No FDA-approved thymulin therapeutic product is established. Studies of zinc, endogenous hormone levels or animal gene delivery do not document an approved peptide treatment.
Preclinical evidence; no FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Human therapeutic benefit
- Formulation, zinc association and stability
- Autoimmune-disease effects and long-term safety
Summary
Changes in endogenous thymulin after zinc supplementation are not evidence that an administered peptide is effective.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedThymulin and human immune-cell cytokines
In-vitro experiment, not administered human treatment.
- pubmedZinc supplementation and endogenous thymulin
Crohn disease study of zinc, not a thymulin regimen.